MAFG-AS1 and urinary bladder carcinoma: In conclusion, this study highlights the critical role of the MAFG-AS1/UCHL5/PCBP2/FPN1 axis in cisplatin resistance in bladder cancer, suggesting that inhibition of MAFG-AS1 may promote ferroptosis and enhance cellular sensitivity to cisplatin treatment (159).